Navigation Links
SomnoDent®G2 FDA 510(k) cleared
Date:6/7/2012

FRISCO, Texas, June 7, 2012 /PRNewswire/ -- SomnoMed Limited (SOM:ASX) is pleased to announce that it has received a 510(k) from the US Food and Drug Administration ("FDA") and will now begin marketing its unique SomnoDent® G2 in the USA. The SomnoDent® G2 technology (patent pending) has been developed over several years, after extensive research and development, following US quality system requirements and the FDA regulatory process.

SomnoDent® G2 will be launched at the 21st Annual Meeting of the Academy of Dental Sleep Medicine and 26th Annual Meeting of the Associated Professional Sleep Society, LLC (APSS) from 7- 13 June 2012 in Boston.

SomnoDent® G2 incorporates modular adjustment parts, which are uniquely identified and provide instant and accurate advancement of the G2 splints. This revolutionary design "Click to Fit" will provide a controlled measurement of a patient's mandible position to treat OSA. The device's range of motion has also been extended providing more treatment options. The SomnoDent® G2 includes SomnoMed's proprietary materials, is metal free and is 20% smaller than SomnoMed's current range of sleep apnea devices, thereby increasing patient comfort.

SomnoDent® G2 will be available through qualified SomnoMed Preferred Dental Network partners only. A newly designed premium packaging and travel case will also protect the device when not in use. Accompanied by an adjustment kit, which stores and organizes the modular adjustment parts, the SomnoDent® G2 represents a new standard of care for Obstructive Sleep Apnea (OSA) patients.

"With the innovative SomnoDent® G2 and Somnomed MATRx® both now FDA cleared we are able to offer state-of-the-art oral appliance treatment and diagnostic solutions for OSA patients never seen before," says CEO Ralf Barschow. "These revolutionary, premium product innovations continue our focus on evidence based, quality clinical outcomes for patients".

For more information please visit SomnoMed at www.somnomed.com or contact:
Ralf Barschow
CEO, SomnoMed Inc.
+1 888 447 6673 Ext. 101
Cell +1 972 742 2995

About SomnoMed
SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism.  SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 100,000 patients in 22 countries.


'/>"/>
SOURCE SomnoMed
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System
2. MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes
3. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
4. Nephros Receives 510(k) Clearance for Hemodiafiltration System
5. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Insightin ... member acquisition, retention, and engagement, announced the selection ... Strategy and Product Development, effective as of February 2017. ... and technology implementation strategy for our clients. Wood ... experience in consulting and business analytics within the ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
Breaking Medicine Technology:
(Date:8/24/2017)... ... August 24, 2017 , ... ... coding, billing and compliance. In the coming months, AudioEducator has lined up several ... all specialties. Delivered by nationally recognized experts, these healthcare training conferences are designed ...
(Date:8/23/2017)... ... August 23, 2017 , ... Loyale Healthcare today ... Mr. Smith joins other recent high-profile hires including Frank Massi, Chief Revenue Officer ... in 1993, helping physician practices and hospitals automate their clinical and financial processes ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... The Stevie® Awards have announced the winners ... Awards , the world’s premier business awards competition. , Nominees in the 2017 IBAs were ... by a points system based on the total number of awards won in the IBAs ...
(Date:8/23/2017)... Indiana (PRWEB) , ... August 23, 2017 , ... ... Whitney Boling, MD , has returned home to Indiana, and is now seeing ... is a board-eligible ophthalmologist that specializes in the diagnosis and treatment of eye ...
(Date:8/23/2017)... Rosa, CA (PRWEB) , ... August 23, 2017 ... ... the Journal of the American Academy of Orthopaedic Surgeons , points out ... for patients suffering from pain or injury. According to the report, a wider ...
Breaking Medicine News(10 mins):